Axsome's (AXSM) Narcolepsy Drug Study Meets Primary Goal [Yahoo! Finance]
Axsome Therapeutics, Inc. (AXSM)
Last axsome therapeutics, inc. earnings: 3/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
axsome.com
Company Research
Source: Yahoo! Finance
The study achieved its primary endpoint of a rapid and significant reduction in weekly cataplexy events. Data from the study showed that treatment with AXS-12 reduced cataplexy attacks by 83% over five weeks compared with 66% for placebo. In fact, treatment with AXS-12 rapidly reduced weekly cataplexy attacks, as it achieved a reduction of 56% in the first week compared to 31% for placebo. Treatment with AXS-12 also induced an increase in remission of cataplexy (100% reduction from baseline) and increased cataplexy-free days (days with zero cataplexy attacks). Per management, 33% of patients who received AXS-12 achieved remission of cataplexy compared to 9.5% of placebo patients. Treatment with the therapy increased the percentage of cataplexy-free days to 84%, compared to 22% for placebo. The drug was also well-tolerated by study participants. In fact, those who received AXS-12 also experienced a reduction in other symptoms of narcolepsy, such as excessive daytime sleepiness (E
Show less
Read more
Impact Snapshot
Event Time:
AXSM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AXSM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AXSM alerts
High impacting Axsome Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AXSM
News
- 15 Most Black States in the US [Yahoo! Finance]Yahoo! Finance
- AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmGlobeNewswire
- Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual MeetingGlobeNewswire
AXSM
Earnings
- 2/20/24 - Miss
AXSM
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEF
- 4/1/24 - Form 4
- AXSM's page on the SEC website